Ardent Health Partners (NYSE:ARDT) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of Ardent Health Partners (NYSE:ARDT) in a report issued on Monday, MarketBeat reports. The firm issued a neutral rating and a $18.00 price objective on the stock.

Several other research firms have also recently weighed in on ARDT. Truist Financial started coverage on shares of Ardent Health Partners in a report on Monday. They set a buy rating and a $21.00 price target on the stock. SVB Leerink began coverage on Ardent Health Partners in a research note on Monday. They issued an outperform rating and a $23.00 target price on the stock. Finally, Mizuho started coverage on Ardent Health Partners in a research report on Monday. They set an outperform rating and a $20.00 price target for the company. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of Buy and an average price target of $21.70.

Ardent Health Partners Stock Up 6.1 %

ARDT opened at $16.97 on Monday. Ardent Health Partners has a 1 year low of $15.00 and a 1 year high of $18.16.

Ardent Health Partners Company Profile

We are the fourth largest privately held, for-profit operator of hospitals and a leading provider of healthcare services in the United States(1). We currently operate in eight growing mid-sized urban markets across six states: Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas. We deliver care through a system of 30 acute care hospitals, more than 200 sites of care, and over 1,700 providers that are either employed by or affiliated with us(2), as of March 31, 2024.